AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39501245 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving intervention with workplace involvement (PSI-WPI) added to care as usual (CAU)
Number of subjects: 199
Study 39501245 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 199
Study 39501337 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid exposure (as-treated analysis)
Number of subjects: 2553
Study 39501337 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid implementation (intention-to-treat analysis)
Number of subjects: 2553
Study 39501337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre vs. post-implementation collaboRATE scores across settings (intention-to-treat)
Number of subjects: 2553
Study 39501340 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of animal-based protein in men
Number of subjects: 8548
Study 39501340 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric deficit and plant-based fat in women
Number of subjects: 8548
Study 39501351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (median dosage 37.00 mg/day at baseline, increased to 74.00 mg/day at 3 months)
Number of subjects: 61
Study 39501351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 61
Study 39501388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (280 mg intravenous single dose)
Number of subjects: 100
Study 39501388 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100
Study 39501801 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR-T therapy
Number of subjects: 108
Study 39501801 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA-based risk model
Number of subjects: 108
Study 39501831 — intervention group
Group type: EXPERIMENTAL
Intervention: Angong Niuhuang Pills (ANP) 3 g/day for 5 days
Number of subjects: 117
Study 39501831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 39501831 — intervention group
Group type: EXPERIMENTAL
Intervention: Angong Niuhuang Pills (ANP)
Number of subjects: 117
Study 39501831 — intervention group
Group type: EXPERIMENTAL
Intervention: Angong Niuhuang Pills (ANP) in patients with large artery atherosclerosis
Number of subjects: 117
Study 39502029 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI (Percutaneous Coronary Intervention)
Number of subjects: 305
Study 39502029 — intervention group
Group type: COMPARATOR
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 305
Study 39502029 — intervention group
Group type: COMPARATOR
Intervention: Overall treatment effect of PCI versus CABG
Number of subjects: 305
Study 39502066 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4605
Study 39502066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4605
Study 39502066 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4605
Study 39502066 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonist
Number of subjects: 4605
Study 39502135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU X3/day)
Number of subjects: 51
Study 39502135 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training
Number of subjects: 51
Study 39502135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 51
Study 39502135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 39502135 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 51
Study 39502155 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based resilience intervention (6 sessions of 55 minutes each over 6 weeks)
Number of subjects: 578
Study 39502155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 578
Study 39502270 — intervention group
Group type: EXPERIMENTAL
Intervention: POC lactate test at hours 0, 1, and 6
Number of subjects: 435
Study 39502270 — intervention group
Group type: EXPERIMENTAL
Intervention: POC lactate test
Number of subjects: 435
Study 39502270 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient of POC lactate from 1st to 2nd sample
Number of subjects: 435
Study 39502454 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 2632
Study 39502454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2632
Study 39502777 — intervention group
Group type: EXPERIMENTAL
Intervention: Somali females
Number of subjects: 139
Study 39502777 — intervention group
Group type: COMPARATOR
Intervention: White females
Number of subjects: 139
Study 39502777 — intervention group
Group type: COMPARATOR
Intervention: Somali males
Number of subjects: 139
Study 39502858 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-focused training
Number of subjects: 40
Study 39502858 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based training
Number of subjects: 40
Study 39502858 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 39503055 — intervention group
Group type: EXPERIMENTAL
Intervention: CellCollector
Number of subjects: 70
Study 39503055 — intervention group
Group type: COMPARATOR
Intervention: Real-time PCR (CEA mRNA)
Number of subjects: 70
Study 39503605 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) predictions of total tumor cellularity (TTC)
Number of subjects: 118
Study 39503605 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) predictions of total tumor volume (TTV)
Number of subjects: 118
Study 39503605 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-predicted TTC for predicting tumor status at the time of surgery
Number of subjects: 118
Study 39503605 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-predicted TTV for predicting tumor status at the time of surgery
Number of subjects: 118
Study 39503757 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Number of subjects: 219
Study 39503757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 39503770 — intervention group
Group type: EXPERIMENTAL
Intervention: CD36 deficiency
Number of subjects: 0
Study 39503770 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting NO bioavailability in CD36 deficiency
Number of subjects: 0
Study 39503798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-guided deprescribing of antihypertensive medications
Number of subjects: 72
Study 39503798 — intervention group
Group type: COMPARATOR
Intervention: Family physician-guided treatment adjustments
Number of subjects: 72
Study 39503807 — intervention group
Group type: EXPERIMENTAL
Intervention: ESK981 + nivolumab
Number of subjects: 10
Study 39503943 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of symptoms
Number of subjects: 413
Study 39503943 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual symptoms (except constipation)
Number of subjects: 413
Study 39503943 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of energy
Number of subjects: 413
Study 39503943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain, lack of energy, drowsiness
Number of subjects: 413
Study 39503942 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE items
Number of subjects: 406
Study 39503942 — intervention group
Group type: EXPERIMENTAL
Intervention: QLQ-C30 scales
Number of subjects: 406
Study 39503942 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE composites
Number of subjects: 406
Study 39504016 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/Amlodipine single-pill combination (SPC) therapy
Number of subjects: 54
Study 39504023 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of mRNA COVID-19 vaccine and quadrivalent inactivated influenza vaccine (IIV4)
Number of subjects: 335
Study 39504023 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration of mRNA COVID-19 vaccine and quadrivalent inactivated influenza vaccine (IIV4)
Number of subjects: 335
Study 39504023 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration
Number of subjects: 335
Study 39504023 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration
Number of subjects: 335
Study 39504025 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased counseling intensity (4 calls)
Number of subjects: 1316
Study 39504025 — intervention group
Group type: COMPARATOR
Intervention: Increased counseling intensity (1 call)
Number of subjects: 1316
Study 39504025 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased nicotine replacement therapy intensity (4-week combination nicotine patch plus nicotine lozenge)
Number of subjects: 1316
Study 39504025 — intervention group
Group type: COMPARATOR
Intervention: Increased nicotine replacement therapy intensity (2-week nicotine patch)
Number of subjects: 1316
Study 39504025 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message support (SmokefreeTXT)
Number of subjects: 1316
Study 39504025 — intervention group
Group type: COMPARATOR
Intervention: No text-message support
Number of subjects: 1316
Study 39504025 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for engagement in counseling and SmokefreeTXT
Number of subjects: 1316
Study 39504025 — intervention group
Group type: COMPARATOR
Intervention: No financial incentives
Number of subjects: 1316
Study 39504026 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient-delivered intervention (3 simulated office visits with feedback)
Number of subjects: 53
Study 39504026 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient-delivered intervention
Number of subjects: 53
Study 39504026 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 53
Study 39504024 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support intervention (physician education, facility-specific audit and feedback, access to decision support)
Number of subjects: 1203
Study 39504024 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1203
Study 39504024 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support used (per protocol)
Number of subjects: 1203
Study 39504024 — intervention group
Group type: COMPARATOR
Intervention: Decision support not used (per protocol)
Number of subjects: 1203
Study 39504090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 289
Study 39504090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 39504267 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative pRBC transfusions
Number of subjects: 1079
Study 39504520 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-start group (immediate start of abortion)
Number of subjects: 1504
Study 39504520 — intervention group
Group type: COMPARATOR
Intervention: Standard group (standard-care treatment delayed until intrauterine pregnancy was confirmed)
Number of subjects: 1504
Study 39504548 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring (RPM+) with digital therapeutics (DTx) solution
Number of subjects: 52
Study 39504548 — intervention group
Group type: COMPARATOR
Intervention: Remote Patient Monitoring (RPM-) without digital therapeutics (DTx) solution
Number of subjects: 52
Study 39504585 — intervention group
Group type: EXPERIMENTAL
Intervention: Samelisant (SUVN-G3031)
Number of subjects: 190
Study 39504585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 39504677 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib, ipilimumab, and nivolumab (RIN)
Number of subjects: 39
Study 39504921 — intervention group
Group type: EXPERIMENTAL
Intervention: TEB (thoracic epidural blockade)
Number of subjects: 30
Study 39504921 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 39504921 — intervention group
Group type: EXPERIMENTAL
Intervention: OLV (one-lung ventilation)
Number of subjects: 30
Study 39504933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 28
Study 39504933 — intervention group
Group type: COMPARATOR
Intervention: Control (wait-list)
Number of subjects: 28
Study 39505110 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO
Number of subjects: 344
Study 39505110 — intervention group
Group type: EXPERIMENTAL
Intervention: GOAL
Number of subjects: 344
Study 39505122 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI in centers with on-site cardiac surgery
Number of subjects: 566
Study 39505122 — intervention group
Group type: COMPARATOR
Intervention: TAVI in centers without on-site cardiac surgery
Number of subjects: 566
Study 39505121 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification intervention informed by behavioral economic concepts; participants receive a wearable fitness tracker and set a goal to increase daily step count by 1,500-3,000 steps from baseline; intervention duration is 6 months.
Number of subjects: 150
Study 39505121 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification intervention;
Number of subjects: 150
Study 39505121 — intervention group
Group type: COMPARATOR
Intervention: Control group;
Number of subjects: 150
Study 39505123 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 466
Study 39505123 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 466
Study 39505152 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased immunosuppression withdrawal (ISW)
Number of subjects: 61
Study 39505279 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (n=95) for 24 months
Number of subjects: 120
Study 39505279 — intervention group
Group type: EXPERIMENTAL
Intervention: No peanut (PN-0) for 12 months (n=51)
Number of subjects: 120
Study 39505279 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg peanut (PN-300) for 12 months (n=30)
Number of subjects: 120
Study 39505279 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=25) for 24 months
Number of subjects: 120
Study 39505286 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical exercise combined with cognitive training
Number of subjects: 127
Study 39505286 — intervention group
Group type: COMPARATOR
Intervention: Home-based physical exercise alone
Number of subjects: 127
Study 39505354 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite with lidocaine
Number of subjects: 0
Study 39505354 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39505933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-omics model
Number of subjects: 1998
Study 39505933 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-omics model for DM patients
Number of subjects: 1998
Study 39506045 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely Interventions for Diabetes Excellence (TIDE)
Number of subjects: 268
Study 39506045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidepool-TIDE (turnkey solution)
Number of subjects: 268
Study 39506184 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Pulsatility Index (API) <1.02
Number of subjects: 120
Study 39506184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Artery Pulsatility Index (PAPI) <2.16
Number of subjects: 120
Study 39506184 — intervention group
Group type: EXPERIMENTAL
Intervention: API <1.02 and PAPI <2.16
Number of subjects: 120
Study 39506184 — intervention group
Group type: COMPARATOR
Intervention: Left Ventricular Ejection Fraction (LVEF)
Number of subjects: 120
Study 39506184 — intervention group
Group type: COMPARATOR
Intervention: Tricuspid Annular Plane Systolic Excursion (TAPSE)
Number of subjects: 120
Study 39506219 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening protocol according to AFSOP recommendations
Number of subjects: 0
Study 39506219 — intervention group
Group type: COMPARATOR
Intervention: Reference ophthalmological examination
Number of subjects: 0
Study 39506293 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP-continuation (n=24); SPP in month 1, continuation treatment in month 2
Number of subjects: 44
Study 39506293 — intervention group
Group type: COMPARATOR
Intervention: Monitoring-SPP (n=20); monitoring in month 1, SPP in month 2
Number of subjects: 44
Study 39506293 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP-continuation (n=24)
Number of subjects: 44
Study 39506499 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled intervention implemented during the intervention period (August 2022-July 2023)
Number of subjects: 1272
Study 39506499 — intervention group
Group type: EXPERIMENTAL
Intervention: Site 3 intervention
Number of subjects: 1272
Study 39506499 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline period)
Number of subjects: 1272
Study 39506499 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 1272
Study 39506529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (PON) 30 mg/day in chronic phase (CP-CML)
Number of subjects: 120
Study 39506529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (PON) 45 mg/day in accelerated/blastic phase (AP/BP-CML)
Number of subjects: 120
Study 39506529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (PON)
Number of subjects: 120
Study 39506539 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic single-bundle (SB) ACL reconstruction
Number of subjects: 120
Study 39506539 — intervention group
Group type: COMPARATOR
Intervention: Anatomic double-bundle (DB) ACL reconstruction
Number of subjects: 120
Study 39506562 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL200
Number of subjects: 207
Study 39506562 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL100
Number of subjects: 207
Study 39506647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballet technique intervention (one-hour classes twice per week for six weeks)
Number of subjects: 4
Study 39506661 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified DBT-informed transdiagnostic psychotherapy group
Number of subjects: 250
Study 39506661 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual group
Number of subjects: 250
Study 39506698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner is served at 1-2-3 euros intervention
Number of subjects: 42
Study 39506698 — intervention group
Group type: EXPERIMENTAL
Intervention: Social organizations' involvement in the intervention
Number of subjects: 42
Study 39506698 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to implementation
Number of subjects: 42
Study 39506698 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' feedback on recipes
Number of subjects: 42
Study 39506698 — intervention group
Group type: EXPERIMENTAL
Intervention: Price guarantee mechanism
Number of subjects: 42
Study 39506737 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity and articulation techniques (HVAT)
Number of subjects: 42
Study 39506737 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-tissue massage (STM)
Number of subjects: 42
Study 39506737 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (CST)
Number of subjects: 42
Study 39506737 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination approach
Number of subjects: 42
Study 39506737 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 42
Study 39506748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure laparoscopic cholecystectomy (LPLC) at 10 mmHg
Number of subjects: 124
Study 39506748 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure laparoscopic cholecystectomy (SPLC) at 14 mmHg
Number of subjects: 124
Study 39506748 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LPLC and SPLC)
Number of subjects: 124
Study 39506784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Activities Score
Number of subjects: 150
Study 39506856 — intervention group
Group type: EXPERIMENTAL
Intervention: TILT-123 (3 × 10^11 to 3 × 10^13 viral particles)
Number of subjects: 52
Study 39506856 — intervention group
Group type: EXPERIMENTAL
Intervention: TILT-123
Number of subjects: 52
Study 39506905 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA plus RIF
Number of subjects: 108
Study 39506905 — intervention group
Group type: COMPARATOR
Intervention: ATRA plus ATO
Number of subjects: 108
Study 39507037 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitors with baseline bone metastasis (BoM)
Number of subjects: 544
Study 39507037 — intervention group
Group type: COMPARATOR
Intervention: PD-1/PD-L1 inhibitors without baseline bone metastasis (BoM)
Number of subjects: 544
Study 39507039 — intervention group
Group type: EXPERIMENTAL
Intervention: TQB2450 (1,200 mg) plus anlotinib (8 mg)
Number of subjects: 534
Study 39507039 — intervention group
Group type: COMPARATOR
Intervention: TQB2450 (1,200 mg) plus placebo
Number of subjects: 534
Study 39507039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 534
Study 39507456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluid therapy
Number of subjects: 2500
Study 39507456 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressor therapy
Number of subjects: 2500
Study 39507456 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of ventilation
Number of subjects: 2500
Study 39507456 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay in ICU
Number of subjects: 2500
Study 39507456 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality in ICU and hospital
Number of subjects: 2500
Study 39507493 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with added Lacticaseibacillus rhamnosus GG (LGG)
Number of subjects: 351
Study 39507493 — intervention group
Group type: COMPARATOR
Intervention: Routine intact cow's milk protein-based formula (Control)
Number of subjects: 351
Study 39507592 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health intervention (DHI)-CoolTaCo
Number of subjects: 60
Study 39507592 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 39507626 — intervention group
Group type: EXPERIMENTAL
Intervention: COMIRESTROKE
Number of subjects: 52
Study 39507857 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Low Intensity Shockwave Therapy (LiSWT)
Number of subjects: 0
Study 39507857 — intervention group
Group type: COMPARATOR
Intervention: Simulated LiSWT (Sham Control)
Number of subjects: 0